Interim Results from Phase 1b/2 Study Evaluating the Combination of Merck ’s KEYTRUDA® (pembrolizumab) and Eisai’s HALAVEN® (eribulin mesylate) Injection in Metastatic Triple-Negative Breast Cancer Presented at 2016 SABCS

Dateline City: KENILWORTH, N.J.& WOODCLIFF LAKE, N.J.KENILWORTH, N.J.& WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced new interim data investigating Merck ’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in combination with Eisai ’s microtubule dynamics inhibitor, HALAVEN® (eribulin), in patients with metastatic triple-negative breast cancer (TNBC).Language: EnglishContact: Media:MerckPamela Eisele, 267-305-3558orKim Hamilton, (908) 740-1863orEisai Inc.Laurie Landau, 201-746-2510orInvestors:MerckTeri Loxam, 908-740-1986orAmy Klug, 908-740-1898orEisai Inc.Ivor Macleod, 201-746-2660Ticker Slug:Ticker:MRKExchange:NYSE @Merckread more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Eisai HALAVEN Keytruda MSD NYSE:MRK Source Type: news